J. Starrett

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

K. Politi, W. Lockwood, Paul D. Smith, 2020, Cancer Research.

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

K. Politi, W. Lockwood, Paul D. Smith, 2020, Cancer Research.

Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

J. Minna, I. Wistuba, K. Politi, 2022, Nature communications.

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

J. Minna, I. Wistuba, K. Politi, 2021, Nature Communications.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

D. Zelterman, S. Gettinger, K. Politi, 2019, Clinical Cancer Research.

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

K. Politi, Paul D. Smith, Z. Cooper, 2022, JCI insight.

Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.

D. Nguyen, K. Politi, Anna Arnal-Estapé, 2021, Cold Spring Harbor perspectives in medicine.